Rybelsus and Ozempic carry nearly identical list prices, both averaging around $959 for a 30-day supply at wholesale acquisition cost. But the price you actually pay depends heavily on whether you’re using insurance, Medicare, or paying cash, and the two drugs can diverge significantly once you move past sticker price.
List Price Is Nearly the Same
Both Rybelsus and Ozempic are made by Novo Nordisk and contain the same active ingredient, semaglutide. The wholesale acquisition cost, which is the baseline price before discounts, is $959 for a 30-day supply of either drug as of 2024. That similarity isn’t a coincidence. Novo Nordisk has priced both products in the same tier despite the different delivery methods (daily pill versus weekly injection).
The Medicare Drug Price Negotiation Program has also set the same maximum fair price for both: $276.78 per package for either an Ozempic pen or a 30-count box of Rybelsus 7mg tablets, effective for 2027.
Cash Prices Favor Ozempic
If you’re paying out of pocket without insurance, the gap between the two drugs becomes dramatic. With a GoodRx coupon, Ozempic’s most common pen configuration runs about $199 to $499 depending on the dose. Rybelsus 14mg, the most commonly prescribed maintenance dose, costs around $1,014 for 30 tablets with a coupon. Even the lowest Rybelsus dose (3mg, used only during the first month of titration) runs about $975 with a discount.
That makes Ozempic roughly 70 to 80 percent cheaper than Rybelsus at the pharmacy counter for cash-pay patients. This is one of the biggest practical differences between the two, and it catches many people off guard since the list prices are so close. The disparity likely reflects deeper discounts and rebate structures that Novo Nordisk has negotiated for the injectable version through pharmacy benefit managers.
Medicare Out-of-Pocket Costs
For Medicare Part D enrollees using either drug for type 2 diabetes, Rybelsus is modestly cheaper. The average monthly out-of-pocket cost for Rybelsus was $52, compared to $60 for Ozempic, based on 2023 data from the Department of Health and Human Services. Over a full year, that adds up: $278 for Rybelsus versus $376 for Ozempic, a savings of about $100 annually.
The type of Medicare plan matters too. Medicare Advantage prescription drug plan enrollees paid significantly less than standalone Part D plan enrollees for both drugs. Rybelsus averaged $41 per month through Medicare Advantage compared to $70 through a standalone plan. Ozempic followed a similar pattern at $46 versus $82. Across all four major GLP-1 drugs, Medicare Advantage enrollees paid about 44 percent less per monthly fill than standalone plan enrollees.
One important caveat: Medicare Part D only covers these drugs for FDA-approved uses like type 2 diabetes, not for weight loss alone. A proposed rule change would expand coverage to include obesity treatment, but that hasn’t taken effect yet.
Commercial Insurance Coverage
With employer-sponsored or marketplace insurance, your copay for either drug depends on your plan’s formulary and tier placement. Both Rybelsus and Ozempic offer manufacturer savings cards for commercially insured patients, which can reduce copays. Neither card is available to people on Medicare or Medicaid.
Prior authorization requirements are generally similar for both drugs. Insurers like Aetna group Rybelsus and Ozempic together in the same GLP-1 drug class and apply the same approval criteria: you typically need to show that you have type 2 diabetes, that you’ve tried or can’t use other treatments, and (for renewals) that your blood sugar levels have improved since starting therapy. Switching from one to the other doesn’t usually trigger a separate prior authorization process since insurers treat them as interchangeable within the class.
How the Doses Compare
Rybelsus and Ozempic aren’t milligram-for-milligram equivalents because oral semaglutide is absorbed far less efficiently than the injected form. Clinical conversion guides match them roughly as follows: Rybelsus 7mg daily is comparable to Ozempic 0.5mg weekly, and Rybelsus 14mg daily is comparable to Ozempic 1mg weekly. The starter dose of Rybelsus (3mg) corresponds to the Ozempic titration dose of 0.25mg.
This means both drugs deliver similar blood sugar control at their equivalent doses, and choosing between them based on price alone is reasonable if your insurance covers both equally. A cost-effectiveness analysis published in Frontiers in Pharmacology found that injectable semaglutide provided a slight clinical edge (an additional 0.04 quality-adjusted life years) over oral semaglutide, though the difference was small enough that cost and personal preference are the more practical deciding factors.
Which One Costs Less for You
The answer depends entirely on how you’re paying:
- Cash pay without insurance: Ozempic is substantially cheaper, often $199 with a coupon versus over $1,000 for Rybelsus.
- Medicare Part D: Rybelsus is slightly cheaper, saving roughly $8 per month or $100 per year on average.
- Commercial insurance: Costs are similar and depend on your plan’s formulary. Check whether your insurer places one on a lower tier than the other, as that will determine your copay.
If you prefer a pill over a weekly injection and have Medicare or good commercial coverage, Rybelsus may cost the same or less. But if you’re paying cash, Ozempic is the clear winner on price right now, and it’s not close.